- Conditions
- Healthy Volunteers, Chronic Kidney Disease
- Interventions
- RBT-9
- Drug
- Lead sponsor
- Renibus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Edgewater, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 53
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Kidney Disease
- Interventions
- Vadadustat
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- Saint Paul, Minnesota • Knoxville, Tennessee
- Conditions
- Cardiovascular Diseases, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5, Vitamin K Deficiency, Hemodialysis
- Interventions
- Vitamin K2 (menaquinone-7; 360-mcg/d), Placebo-Control
- Dietary Supplement
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Chronic Kidney Disease, Diabetic Nephropathy
- Interventions
- Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 24
- States / cities
- Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more
- Conditions
- CKD Stage 3, CKD Stage 4, CKD Stage 5
- Interventions
- EndoAVF System for endovascular AV fistula creation
- Device
- Lead sponsor
- California Institute of Renal Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Escondido, California
- Conditions
- CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
- Interventions
- CTAP101
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
- Conditions
- Chronic Kidney Diseases, Chronic Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Chronic Kidney Disease Stage 5, Hypertension
- Interventions
- Control-EDI, Intervention-EDI, Health coaching
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 11
- States / cities
- Ann Arbor, Michigan • Brighton, Michigan • Canton, Michigan + 6 more
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
- Interventions
- CTAP101, Placebo
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Greenville, South Carolina
- Conditions
- Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4
- Interventions
- Sulforaphane (Avmacol Extra Strength), Placebo
- Drug · Dietary Supplement
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Chronic Kidney Disease
- Interventions
- Sevelamer carbonate, Calcium acetate
- Drug
- Lead sponsor
- Albany College of Pharmacy and Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Chronic Kidney Failure
- Interventions
- Not listed
- Lead sponsor
- Kibow Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Brooklyn, New York
- Conditions
- Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Diabetes
- Interventions
- DM199
- Drug
- Lead sponsor
- DiaMedica Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 3
- States / cities
- Hialeah, Florida • Orlando, Florida • Saint Paul, Minnesota
- Conditions
- Anemia, Kidney Disease
- Interventions
- AKB-6548
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Augusta, Georgia • San Antonio, Texas
- Conditions
- Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
- Interventions
- Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
- Device · Drug
- Lead sponsor
- Truway Health, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Kidney Disease, Anemia
- Interventions
- Roxadustat, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 34
- States / cities
- Peoria, Arizona • Tempe, Arizona • Los Angeles, California + 31 more
- Conditions
- Chronic Kidney Disease (Stage 3-4), Chronic Kidney Disease (Stages 4 and 5), Proteinuria
- Interventions
- QRX-3, Eseronate
- Drug
- Lead sponsor
- Neukidney Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Pasadena, Texas
- Conditions
- Chronic Kidney Disease
- Interventions
- Diet counseling, Phosphorus binder
- Other · Drug
- Lead sponsor
- Salem Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Salem, Virginia
- Conditions
- Chronic Kidney Disease
- Interventions
- 1500 mg/d elemental calcium as calcium carbonate, Placebo
- Dietary Supplement
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Secondary Hyperparathyroidism-Chronic Kidney Disease
- Interventions
- Doxercalciferol (GZ427397), Calcitriol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
- Interventions
- Placebo, Sotagliflozin
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 34
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
- Conditions
- Chronic Kidney Disease (Stage 3-4), Chronic Kidney Disease Mineral and Bone Disorder
- Interventions
- Dietary Phosphorus Intake
- Dietary Supplement
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Chronic Kidney Failure
- Interventions
- Kibow Biotics/Renadyl
- Dietary Supplement
- Lead sponsor
- Kibow Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Kidney Disease (Stage 3-4), Vascular Function, Cognitive Functions, Cerebrovascular Function, Blood Pressure
- Interventions
- Equol, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Kidney Diseases
- Interventions
- Lanthanum carbonate, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Torrance, California • Thornton, Colorado + 7 more